Jazz Pharmaceuticals Announces Third Quarter 2009 Financial Results

-Achieved Record Quarterly Net Product Sales of $30 Million

PALO ALTO, Calif., Nov. 5 /PRNewswire-FirstCall/ -- Jazz Pharmaceuticals, Inc.
(Nasdaq: JAZZ) today announced financial results for the third quarter ended
September 30, 2009.

Total revenues for the third quarter of 2009 were $30.8 million, compared to
$17.7 million for the quarter ended September 30, 2008. XYREM® (sodium
oxybate) oral solution net sales for the third quarter of 2009 were $25.0
million, compared to $14.2 million for the third quarter of 2008, and
represented a 12% sequential increase over net sales of $22.4 million for the
second quarter of 2009. Net sales of once-daily LUVOX CR® (fluvoxamine
maleate) extended-release capsules were $5.0 million for the third quarter of
2009, compared to $2.0 million for the third quarter 2008, and represented a
20% sequential increase over net sales of $4.1 million for the second quarter
of 2009. Total revenues for the third quarter of 2009 also included $0.8
million in royalties and contract revenue.

"Our sales team delivered another solid quarter for us with record numbers of
XYREM and LUVOX CR prescriptions and net sales" said Bob Myers, President of
Jazz Pharmaceuticals.

Research and development expenses for the third quarter of 2009 were $7.6
million, compared to $12.1 million for the third quarter of 2008. This
reduction from $11.2 million for the second quarter of 2009 was primarily due
to the completion of the second Phase III pivotal clinical efficacy trial for
JZP-6, sodium oxybate for the treatment of fibromyalgia, in June of 2009. Jazz
Pharmaceuticals expects to submit a New Drug Application for JZP-6 by the end
of 2009.

Jazz Pharmaceuticals' net loss for the third quarter of 2009 was $1.7 million,
compared to a net loss of $28.8 million for the third quarter of 2008.

Jazz Pharmaceuticals is increasing its full-year 2009 guidance for XYREM and
LUVOX CR net sales, and tightening its guidance for R&D expenses:

Prior Guidance Updated Guidance
-------------- ----------------
- Total revenues $112 - 122 million $122 - 127 million
- XYREM net sales $85 - 90 million $92 - 95 million
- LUVOX CR net sales $15 - 18 million $17 - 19 million
- Contract revenues
and royalties $12 - 14 million ~ $13 million
- R&D expenses $35 - 45 million $36 - 40 million

"We have made impressive strides in transforming our business in 2009," said
Bruce Cozadd, Chairman and Chief Executive Officer of Jazz Pharmaceuticals.
"In the first nine months of 2008, we had net product sales of $45.8 million
and an operating loss of $118.6 million. In the first nine months of 2009, we
achieved net product sales of $77.8 million and operating income of $4.5
million. Our commercial business continues to grow and we look forward to
submitting our NDA for JZP-6 next month."

Jazz Pharmaceuticals will host an investor conference call and live audio
webcast to give a company update, as well as to discuss financial results and
guidance, today (November 5, 2009) commencing at 5:00 p.m. Eastern Time/2:00
p.m. Pacific Time. The live webcast may be accessed from the Investors section
of the Jazz Pharmaceuticals website at www.JazzPharmaceuticals.com. Please
connect to the website prior to the start of the conference call to ensure
adequate time for any software downloads that may be necessary. Investors may
participate in the conference call by dialing 1-866-825-1692 in the U.S., or
1-617-213-8059 outside the U.S., and entering passcode 25459996.

An archived version of the webcast will be available through November 19,
2009. This replay can be accessed from the Investors section of the Jazz
Pharmaceuticals' website at www.JazzPharmaceuticals.com, or by calling
888-286-8010 in the U.S., or 617-801-6888 outside the U.S., and entering
passcode 83883148.

About Jazz Pharmaceuticals, Inc.
Jazz Pharmaceuticals is a specialty pharmaceutical company focused on
identifying, developing and commercializing innovative products to meet unmet
medical needs in neurology and psychiatry. For further information see
www.JazzPharmaceuticals.com.

"Safe Harbor" Statement under the Private Securities Litigation Reform Act of
1995
This press release contains forward-looking statements, including, but not
limited to, statements related to Jazz Pharmaceuticals' ability to
appropriately grow net product sales, the expected New Drug Application
submission date for the JZP-6 product candidate, and Jazz Pharmaceuticals'
full-year 2009 guidance. These forward-looking statements are based on the
company's current expectations and inherently involve significant risks and
uncertainties. Jazz Pharmaceuticals' actual results and the timing of events
could differ materially from those anticipated in such forward looking
statements as a result of these risks and uncertainties, which include,
without limitation, risks related to: Jazz Pharmaceuticals' ability to
increase sales of XYREM and LUVOX CR; Jazz Pharmaceuticals' dependence on
single source suppliers and manufacturers; the uncertain and time-consuming
regulatory approval process for JZP-6; Jazz Pharmaceuticals' cash flow
estimates; Jazz Pharmaceuticals' ability to use its net operating losses to
offset taxes; competition; the holders of Jazz Pharmaceuticals' senior secured
notes attempting to accelerate the notes as a result of past events of default
or Jazz Pharmaceuticals' inability to comply with the terms of the agreement
governing the senior secured notes on an ongoing basis; Jazz Pharmaceuticals'
future financial performance and financial position; and those risks detailed
from time-to-time under the caption "Risk Factors" and elsewhere in Jazz
Pharmaceuticals' Securities and Exchange Commission filings and reports,
including in its Quarterly Report on Form 10-Q for the quarter ended June 30,
2009 filed by Jazz Pharmaceuticals with the Securities and Exchange Commission
on August 14, 2009. Jazz Pharmaceuticals undertakes no duty or obligation to
update any forward-looking statements contained in this release as a result of
new information, future events or changes in its expectations.

JAZZ PHARMACEUTICALS, INC.
CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except per share amounts)
(Unaudited)

Three Months
Ended September Nine Months Ended
30, September 30,
---------------- -----------------
2009 2008 2009 2008
---- ---- ---- ----
Revenues:
Product sales, net $29,992 $17,022 $77,789 $45,757
Royalties, net 532 440 1,522 1,308
Contract revenues 285 284 10,854 854
--- --- ------ ---
Total revenues 30,809 17,746 90,165 47,919
Operating expenses:
Cost of product sales 2,338 5,525 6,856 10,619
Research and development 7,644 12,149 30,244 55,274
Selling, general
and administrative 15,061 24,329 42,934 91,218
Amortization of
intangible assets 2,057 3,487 5,611 9,454
----- ----- ----- -----
Total operating expenses 27,100 45,490 85,645 166,565
------ ------ ------ -------
Income (loss)
from operations 3,709 (27,744) 4,520 (118,646)
Interest income 2 353 29 1,700
Interest expense (5,384) (5,355) (17,034) (14,377)
Other income
(expense), net 1 19 (4) 6
Gain on sale of
product rights - 3,918 - 3,918
- ----- - -----
Net loss $(1,672) $(28,809) $(12,489) $(127,399)
======= ======== ======== =========

Net loss per share:
Basic and diluted $(0.05) $(1.07) $(0.42) $(5.12)
====== ====== ====== ======

Weighted-average common
shares used in computing
net loss per share:
Basic and diluted 30,895 27,025 29,635 24,895
====== ====== ====== ======

JAZZ PHARMACEUTICALS, INC.
SUMMARY OF PRODUCT SALES, NET
(In thousands)
(Unaudited)

Three Months Nine Months
Ended Ended
September 30, September 30,
-------------- --------------
2009 2008 2009 2008
---- ---- ---- ----
Xyrem $25,038 $14,234 $65,119 $37,980
Luvox CR 4,954 1,957 12,670 2,671
Antizol and Antizol-Vet (1) - 831 - 5,106
- --- - -----
Total $29,992 $17,022 $77,789 $45,757
======= ======= ======= =======

(1) The Company sold its rights to and interests in Antizol and
Antizol-Vet in August 2008.

JAZZ PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands)
(Unaudited)
September 30, December 31,
2009 2008
---- ----
ASSETS
Current assets:
Cash and cash equivalents $12,230 $24,903
Restricted cash 950 1,913
Marketable securities - 1,004
Accounts receivable 9,202 6,643
Inventories 4,532 4,788
Prepaid expenses 1,969 2,366
Other current assets 261 2,382
--- -----
Total current assets 29,144 43,999
Property and equipment, net 1,444 2,514
Intangible assets, net 31,915 32,526
Goodwill 38,213 38,213
Other long-term assets 1,456 246
----- ---
Total assets $102,172 $117,498
======== ========

LIABILITIES AND STOCKHOLDERS' DEFICIT
Current liabilities:
Accounts payable $5,240 $5,736
Accrued liabilities 21,370 19,024
Line of credit 3,000 3,875
Senior secured notes - 118,534
Purchased product rights liability 6,000 14,000
Deferred revenue 2,500 12,322
----- ------
Total current liabilities 38,110 173,491
Deferred rent 7 -
Purchased product rights liability, noncurrent 10,000 -
Deferred revenue, noncurrent 10,476 11,330
Liability under government settlement,
noncurrent 10,658 13,063
Senior secured notes 115,363 -
Common stock subject to repurchase - 12,492
Total stockholders' deficit (82,442) (92,878)
------- -------
Total liabilities and stockholders' deficit $102,172 $117,498
======== ========

SOURCE Jazz Pharmaceuticals, Inc.

Karen L. Bergman, +1-650-575-1509, or Michelle Corral, +1-415-794-8662, both
of BCC Partners on behalf of Jazz Pharmaceuticals, Inc.; or Willie Quinn,
Executive Director, Corporate Development of Jazz Pharmaceuticals, Inc.,
investorinfo@jazzpharmaceuticals.com